Pharmacokinetics, Safety, and Tolerability of AZD5462 in Patients with Renal Impairment: A Clinical Investigation

The primary objective of this study is to evaluate the **pharmacokinetics**, safety, and tolerability of AZD5462 in participants with **impaired renal function**. Understanding the pharmacokinetics in this population is clinically relevant as it helps to determine appropriate dosing regimens and ensures the safe use of AZD5462 in patients with varying degrees of renal impairment. The study aims to provide insights into how renal impairment affects the drug's absorption, distribution, metabolism, and excretion, which is crucial for optimizing therapeutic outcomes and minimizing potential adverse effects.

The clinical trial involves participants with **impaired renal function**. The study population includes both male and female subjects, with an age range spanning from adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to evaluate the **pharmacokinetics**, safety, and tolerability of AZD5462 in participants with **impaired renal function**. This study is a Phase 3 trial, which is expected to commence recruitment on October 18, 2024, and conclude by June 7, 2025. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive either the investigational product or a control, with neither the participants nor the investigators aware of the group assignments, thus maintaining the integrity of the blinding process.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful screening, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participants' health status, assess the pharmacokinetics of the investigational product, and evaluate any adverse events or side effects. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data on the trial's endpoints.

The expected length of participant involvement in the trial is determined by the study's duration, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. These conditions are in place to ensure the safety and well-being of the participants throughout the trial. The trial's design and procedures are meticulously structured to achieve the study's objectives while maintaining the highest ethical and scientific standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on October 18, 2024, with an estimated completion date of June 7, 2025. The efficacy assessment will be conducted through a series of predefined endpoints, although specific primary and secondary endpoints are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The methodology for measuring efficacy will adhere to standard clinical trial practices, utilizing validated tools and instruments where applicable. The trial's design and execution will align with regulatory standards to ensure the integrity and validity of the efficacy outcomes.